Fasidotril Eli Lilly.

Abstract

Lilly is developing fasidotril, a diester prodrug of the active metabolite fasidotrilat, for the potential treatment of hypertension and congestive heart failure (CHF). Phase II trials to investigate the potential of fasidotril for the treatment of hypertension and CHF had commenced by the late 1990s, and were ongoing in July 2003 in the US and Europe.

• Authors: Fatih Ozdener, Vural Ozdemir
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 4 Issue 9 Pg. 1113-9 (Sep 2003) ISSN: 1472-4472 [Print] England
• PMID: 14582457 (Publication Type: Journal Article, Review)

Chemical References

• Angiotensin-Converting Enzyme Inhibitors
• Antihypertensive Agents
• Protease Inhibitors
• aladotril
• Alanine

Topics

• Alanine (administration & dosage, analogs & derivatives, chemistry, therapeutic use)
• Angiotensin-Converting Enzyme Inhibitors (administration & dosage, chemistry, therapeutic use)
• Antihypertensive Agents (administration & dosage, chemistry, therapeutic use)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Heart Failure (drug therapy, enzymology)
• Humans
• Hypertension, Renovascular (drug therapy, enzymology)
• Molecular Structure
• Protease Inhibitors (administration & dosage, chemistry, therapeutic use)
• Randomized Controlled Trials as Topic
• Structure-Activity Relationship